Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $26.55 million. The enterprise value is $12.16 million.
Important Dates
The next estimated earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 8.85 million shares outstanding. The number of shares has increased by 16.80% in one year.
| Current Share Class | 8.85M |
| Shares Outstanding | 8.85M |
| Shares Change (YoY) | +16.80% |
| Shares Change (QoQ) | -6.04% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 8.78% |
| Float | 8.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2,713.73 |
| Forward PS | 2.80 |
| PB Ratio | -4.42 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.51 |
| P/OCF Ratio | 4.92 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,242.44 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 2.52 |
Financial Position
The company has a current ratio of 0.85
| Current Ratio | 0.85 |
| Quick Ratio | 0.74 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.27 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -67.57% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -4,765.42% |
| Revenue Per Employee | $425 |
| Profits Per Employee | -$176,243 |
| Employee Count | 23 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.92% in the last 52 weeks. The beta is 1.34, so Daré Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -15.92% |
| 50-Day Moving Average | 2.98 |
| 200-Day Moving Average | 3.30 |
| Relative Strength Index (RSI) | 56.78 |
| Average Volume (20 Days) | 17,132 |
Short Selling Information
The latest short interest is 62,355, so 0.70% of the outstanding shares have been sold short.
| Short Interest | 62,355 |
| Short Previous Month | 87,442 |
| Short % of Shares Out | 0.70% |
| Short % of Float | 0.72% |
| Short Ratio (days to cover) | 3.05 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of $9,784 and -$4.05 million in losses. Loss per share was -$0.48.
| Revenue | 9,784 |
| Gross Profit | -14.30M |
| Operating Income | -23.45M |
| Pretax Income | -28.87M |
| Net Income | -4.05M |
| EBITDA | -23.41M |
| EBIT | -23.45M |
| Loss Per Share | -$0.48 |
Full Income StatementBalance Sheet
The company has $15.70 million in cash and $1.30 million in debt, giving a net cash position of $14.40 million or $1.63 per share.
| Cash & Cash Equivalents | 15.70M |
| Total Debt | 1.30M |
| Net Cash | 14.40M |
| Net Cash Per Share | $1.63 |
| Equity (Book Value) | -6.01M |
| Book Value Per Share | -0.69 |
| Working Capital | -3.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $5.39 million and capital expenditures -$573,046, giving a free cash flow of $4.82 million.
| Operating Cash Flow | 5.39M |
| Capital Expenditures | -573,046 |
| Free Cash Flow | 4.82M |
| FCF Per Share | $0.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -239,692.20% |
| Pretax Margin | -41,430.90% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | 49,276.38% |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.80% |
| Shareholder Yield | -16.80% |
| Earnings Yield | -15.27% |
| FCF Yield | 18.16% |
Analyst Forecast
The average price target for Daré Bioscience is $20.33, which is 577.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.33 |
| Price Target Difference | 577.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 762.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 0.0833333:1.
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0833333:1 |
Scores
Daré Bioscience has an Altman Z-Score of -14.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.03 |
| Piotroski F-Score | 2 |